Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis Development of BIIB105, an investigational antisense oligonucleotide for amyotrophic lateral sclerosis (ALS), will be discontinued based on data from the Phase 1/2 ALSpire studyBiogen and Ionis continue their long-standing commitment to developing therapies for ALS given the devastating impact of this progressive, fatal neurodegenerative condition CAMBRIDGE, Mass. and CARLSBAD, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- Inc. (Nasdaq: BIIB) and (Nasdaq: IONS) announced the de...
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status TOKYO and CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai has initiated the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administra...
Moody's Ratings (Moody's) assigned Aaa ratings to the new USD and EUR denominated senior unsecured note offerings of Johnson & Johnson ("J&J"). There are no changes to J&J's existing ratings including the Aaa senior unsecured long-term rating or the Prime-1 short-term rating. The outlook remains unc...
AMN Healthcare Announces First Quarter 2024 Results Quarterly revenue of $821 million; GAAP EPS of $0.45 and adjusted EPS of $0.97 DALLAS, May 09, 2024 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations across the United States, today announced its first quarter 2024 financial results. Financial highlights are as follows: Dollars in millions, except per share amounts. Q1 2024% Change Q1 2023Revenue$820.9(27%) Gross profit$257.5(30%) Net income$17.3(79%) GAAP diluted EPS$0.45(78%) Adjusted dilute...
Survey: Nurses See Little Improvement in 2024 Over One-Third Extremely Likely to Change Jobs DALLAS, May 06, 2024 (GLOBE NEWSWIRE) -- The majority of nurses (80%) think 2024 will be either no better or worse for nurses than 2023, according to a new survey by AMN Healthcare, the nation’s leading healthcare workforce solutions company. Forty-two percent said 2024 will be the same for nurses as 2023, 38% said it will be worse, while only 20% said it will be better. “Nurses weathered the storm of COVID-19, but many still see clouds ahead for the profession,” said Robin Johnson, Group Presi...
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that Andrew Baum, M.D., will join the company as Chief Strategy and Innovation Officer, Executive Vice President. Dr. Baum will be a member of Pfizer’s Executive Leadership Team reporting to Chairman and Chief Executive Officer, Dr. Albert Bourla. He joins Pfizer from Citi, where he served as Head of Global Healthcare, Managing Director Equity Research. Prior to joining Citi in 2011, Dr. Baum covered European Pharmaceuticals at Morgan Stanley for 14 years and earlier in his career was a practicing physician at the Royal Nation...
Biogen Reports Progress on Corporate Responsibility Priorities Efforts focused on four areas: access and health equity, workforce and DE&I, community impact and the environment CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Inc. (Nasdaq: BIIB) today announced publication of its detailing progress on the company’s commitment to making responsible business decisions in the best interests of all its stakeholders. “As we reflect on the past year and set our sights on the path ahead, I am truly inspired by the progress we have made to advance Biogen’s enduring legacy of pioneering inno...
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2024 and raised its Adjusted(3) diluted EPS guidance while maintaining all other components of its 2024 financial guidance(6). The first-quarter 2024 earnings presentation and accompanying prepared remarks from management as well as the quarterly update to Pfizer’s R&D pipeline can be found at . EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and Chief Executive Officer, stated: “We delivered strong performance in our non-COVID product portfolio in the first quarter of 2024, including...
Moody's Ratings (Moody's) affirmed the ratings of Eli Lilly and Company ("Lilly") including the A1 senior unsecured notes and issuer rating. At the same tome Moody's also affirmed the (P)A1 senior unsecured shelf, (P)A1 senior unsecured medium term notes program and the Prime-1 short-term rating. Mo...
NEW YORK & COPENHAGEN, Denmark--(BUSINESS WIRE)-- (NYSE: PFE) and (Nasdaq: GMAB) today announced the U.S. Food and Drug Administration (FDA) approves the supplemental Biologics License Application (sBLA) granting full approval for TIVDAK® (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. "Recurrent or metastatic cervical cancer is a particularly devastating and mostly incurable disease, and patients are in need of survival-extending treatment options,” said Chris Boshoff, M.D., Ph.D., Chief...
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) highlights its progress in advancing new potential standards of care in Oncology at the 2024 American Society of Clinical Oncology (ASCO®) Annual Meeting, taking place May 31 to June 4 in Chicago. More than 50 abstracts, including 11 oral presentations, will be presented from Pfizer’s broadened portfolio of approved and pipeline therapies across the company’s key tumor areas and core scientific modalities, including small molecules, antibody-drug conjugates (ADCs) and bispecific antibodies. “We are excited to participate in our first ASCO A...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved BEQVEZ™ (fidanacogene elaparvovec-dzkt) for the treatment of adults with moderate to severe hemophilia B who currently use factor IX (FIX) prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes, and do not have neutralizing antibodies to adeno-associated virus serotype Rh74var (AAVRh74var) capsid as detected by an FDA-approved test. BEQVEZ is a one-time treatment that is designed to ena...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.